Richard Nathan - Concepedia

Author

Richard Nathan

Clinical Trials of Texas

Also Known As

Bharat Misra, Kara Turner, Richard A. Nathan, Richard Nathan

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Clinical Trials of Texas Sanford Research Ventura College PMG Research Sanofi (United States)

About

Richard Nathan is an author at Clinical Trials of Texas specializing in health sciences, medicine, and antibiotics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	4	4	57
2	Medicine	4	4	57
3	Microbiology	3	3	39
4	Immunology	1	1	18
5	Obstetrics	1	1	11

Richard Nathan

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection Mark H. Wilcox, Dale N. Gerding, Ian R. Poxton, New England Journal of Medicine	2017	832
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults Carlos A. DiazGranados, Andrew J. Dunning, Murray Kimmel, New England Journal of Medicine	2014	820
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study Richard Vickers, Glenn Tillotson, Richard Nathan, The Lancet Infectious Diseases	2017	115
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial Guy de Bruyn, Jamshid Saleh, David Workman, Vaccine	2016	95
Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II) Mark Wilcox, Dale N. Gerding, Ian R. Poxton, Open Forum Infectious Diseases ImmunologyCare AntibioticsPharmacotherapyAntimicrobial ChemotherapyImmunotherapy	2015	18
S131 CP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial Sahil Khanna, Colleen Kelly, Thomas Louie, The American Journal of Gastroenterology DysbiosisPlacebo-controlled TrialDrug ResistanceAntimicrobial StewardshipGut Microbiology	2021	17
Extremely Low Excretion of Daptomycin into Breast Milk of a Nursing Mother with Methicillin‐Resistant <i>Staphylococcus aureus</i> Pelvic Inflammatory Disease Martha Buitrago, Jason A. Crompton, Shellie Bertolami, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy Nursing MotherAntimicrobial SusceptibilityHealth SciencesAntibioticsHealthcare-associated Infection	2009	11
1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI) Christopher B. Ford, Kevin Litcofsky, Barbara McGovern, Open Forum Infectious Diseases DysbiosisMicrobial PathogensAntibiotic ResistanceBacterial PathogensDrug Resistance	2019	11
Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer Oliver A. Cornely, Kathleen M. Mullane, Thomas Birch, Open Forum Infectious Diseases	2020	11

Page 1